CoChat

A Blood-Based, 7-Metabolite Signature for the Early Diagnosis of Alzheimer's Disease

Open access
Olazarán, Javier, Gil-de-Gómez, Luis, Rodríguez-Martín, Andrés, Valentí-Soler, Meritxell, Frades-Payo, Belén, Marín-Muñoz, Juan, Antúnez, Carmen, Frank-García, Ana, Acedo-Jiménez, Carmen, Morlán-Gracia, Lorenzo, Petidier-Torregrossa, Roberto, Guisasola, María Concepción, Bermejo-Pareja, Félix, Sánchez-Ferro, Álvaro, Pérez-Martínez, David A., Manzano-Palomo, Sagrario, Farquhar, Ruth, Rábano, Alberto, Calero, Miguel · 2015 · Journal of Alzheimer’s Disease
Cited by 115

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

Accurate blood-based biomarkers of Alzheimer's disease (AD) could constitute simple, inexpensive, and non-invasive tools for the early diagnosis and treatment of this devastating neurodegenerative disease. We sought to develop a robust AD biomarker panel by identifying alterations in plasma metabolites that persist throughout the continuum of AD pathophysiology. Using a multicenter, cross-sectional study design, we based our analysis on metabolites whose levels were altered both in AD patients and in patients with amnestic mild cognitive impairment (aMCI), the earliest identifiable stage of AD. UPLC coupled to mass spectrometry was used to independently compare the levels of 495 plasma metabolites in aMCI (n = 58) and AD (n = 100) patients with those of normal cognition controls (NC, n = 93). Metabolite alterations common to both aMCI and AD patients were used to generate a logistic regression model that accurately distinguished AD from NC patients. The final panel consisted of seven metabolites: three amino acids (glutamic acid, alanine, and aspartic acid), one non-esterified fatty acid (22:6n-3, DHA), one bile acid (deoxycholic acid), one phosphatidylethanolamine [PE(36:4)], and one sphingomyelin [SM(39:1)]. Detailed analysis ruled out the influence of potential confounding variables, including comorbidities and treatments, on each of the seven biomarkers. The final model accurately distinguished AD from NC patients (AUC, 0.918). Importantly, the model also distinguished aMCI from NC patients (AUC, 0.826), indicating its potential diagnostic utility in early disease stages. These findings describe a sensitive biomarker panel that may facilitate the specific detection of early-stage AD through the analysis of plasma samples.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jad-142925

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 115

Metadata

Authors
Olazarán, J., Gil-de-Gómez, L., Rodríguez-Martín, A., Valentí-Soler, M., Frades-Payo, B., Marín-Muñoz, J., Antúnez, C., Frank-García, A., Acedo-Jiménez, C., Morlán-Gracia, L., Petidier-Torregrossa, R., Guisasola, M. C., Bermejo-Pareja, F., Sánchez-Ferro, Á., Pérez-Martínez, D. A., Manzano-Palomo, S., Farquhar, R., Rábano, A., & Calero, M.
Venue
Journal of Alzheimer’s Disease
Published
2015-04-13
Volume
45
Issue
4
Pages
1157-1173
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
OpenAlex
W1509269112
Cited by
115
References
24
FWCI
7.96
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Blood-Based, 7-Metabolite Signature for the Early Diagnosis of Alzheimer's Disease. https://app.cochat.ai/papers/10.3233/jad-142925
The paper
Olazarán, J., Gil-de-Gómez, L., Rodríguez-Martín, A., Valentí-Soler, M., Frades-Payo, B., Marín-Muñoz, J., Antúnez, C., Frank-García, A., Acedo-Jiménez, C., Morlán-Gracia, L., Petidier-Torregrossa, R., Guisasola, M. C., Bermejo-Pareja, F., Sánchez-Ferro, Á., Pérez-Martínez, D. A., Manzano-Palomo, S., Farquhar, R., Rábano, A., & Calero, M. (2015). A Blood-Based, 7-Metabolite Signature for the Early Diagnosis of Alzheimer's Disease. Journal of Alzheimer’s Disease. https://doi.org/10.3233/jad-142925

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.